Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024
Tubulis announced today that Fierce Biotech has named the company as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most...
Search
All
Tubulis announced today that Fierce Biotech has named the company as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most...
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...
Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...
Source : La Gazette du LABORATOIRE
©LaGazetteDuLABORATOIRE
Starfish Bioscience aims to provide microbiological solutions to restore the soil microbiome for...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Khosla...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...